Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiome Changes Following Liraglutide Treatment
NCT04525300Phase 3Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Liraglutide with Placebo (2 arms). Primary endpoint: Composition of the gut microbiota at week 28. Status: unknown.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04525300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525300.